Ulcerative colitis (UC) patients, particularly those with more mild disease activity, will be prescribed a conventional therapy (e.g., 5-ASAs) as first-line treatment; there are multiple generics…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
ACS is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. Current drug targets for ACS, particularly those in the acute…
MARKET OUTLOOK Asthma pharmacotherapy has two main goals: address underlying airway inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals—…
The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced…
In an attempt to mitigate postoperative pain following surgical procedures, patients may be administered analgesics/anesthetics intraoperatively, postoperatively, and at hospital discharge. Opioids…
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-…
NSCLC is one of the most dynamic indications in oncology. In the United States, the FDAapproved six new therapies for NSCLC in 2015 and, in 2016, granted approval to Tecentriq (Roche/Genentech…
Hormonal therapy is the mainstay of prostate cancer, in all stages of disease and clinical settings. The adoption of novel hormonal agents, Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/…
Following the European Medicines Agency’s approvals of the PDE-4 inhibitor Otezla and the IL-17 inhibitor Cosentyx for psoriatic arthritis (PsA), treatment of this disease in the EU5 has begun to…
Once limited to ankylosing spondylitis (AS), the axial spondyloarthritis (AxSpA) therapy market is undergoing rapid change as the definition of the disease expands beyond those with detectable…
The relatively recent FDA approvals of tedizolid (Merck’s Sivextro), dalbavancin (Allergan’s Dalvance), and oritavancin (The Medicines Company’s Orbactiv) for the treatment of acute bacterial…
Obesity is a growing epidemic in the United States. Despite the high prevalence, only a limited number of antiobesity drugs are available, and lifestyle interventions remain the cornerstone of…
Antineoplastic treatment in stage IV renal cell carcinoma is with targeted agents. The market entry of an immune checkpoint inhibitor has revolutionized the treatment algorithm for previously…